3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Hepatocellular
19
Neoplasm Metastasis
13
Melanoma
12
Nasopharyngeal Carcinoma
10
Carcinoma, Non-Small-Cell Lung
10
Stomach Neoplasms
8
Rectal Neoplasms
8
Pancreatic Neoplasms
8
Colorectal Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Neoplasms
6
Locally Advanced Rectal Cancer
6
Carcinoma, Renal Cell
6
Uterine Cervical Neoplasms
4
Recurrence
4
Lymphoma, Extranodal NK-T-Cell
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Nasopharyngeal Neoplasms
3
Glioblastoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Cholangiocarcinoma
3
Thyroid Neoplasms
2
Solid Tumor
2
Prostatic Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Gastrointestinal Stromal Tumors
2
Interventions
spartalizumab
1
sintilimab
1
pyrotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Digestive System Tumor
×
spartalizumab
×
Clear all
NCT07053150
2025-07-08
CCGLC-018
Tongji Hospital
Phase 2
Not yet recruiting
80 enrolled